Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2000

View Archived Issues

Cerus continues phase III trial of platelet pathogen inactivation system in Europe

Two additional U.S. patents allowed for Maxamine technology

NPS Allelix drug candidate enhances bone growth in space shuttle experiments

Arena and Fujisawa establish collaboration in neurodegenerative disease area

Cambridge Drug Discovery and Parke-Davis complete screening collaboration

IND filed for nasal leuprolide as endometriosis therapy

Telik initiates clinical testing of first development candidate

Novel agent for treatment-refractory CIS now under review in Canada

Idun and Elan establish stroke therapy collaboration

Novel isatin derivatives with broad-spectrum antibacterial and antifungal activity

Alexion to commence development of 5G1.1 for treatment of dermatomyositis

Elan establishes new agreement with Wyeth-Ayerst for integrin inhibitors

Combidex contrast agent receives priority review status from FDA

Focus on carbapenem modifications continues at Merck

Emtricitabine-containing HAART regimen is highly efficacious in French study

Potent, broad-spectrum cephalosporins in development at Roche

Preliminary results in volunteers reinforce the promise of DuPont's second-generation NNRTIs

Incyte patents novel GFMOs for cancer and fibrotic disorders

Boston Life Sciences identifies target of CNS growth factor products

Novel 5-HT7 antagonists for CNS disorders under investigation at DuPont

Lilly describes 5-HT1F agonists as potential antimigraine agents

Aventis Behring launched

Lilly assesses potential utility of PLA2 inhibitors for septic shock

Roxane launches orphan drug for treatment of apnea in premature infants

BMS informs of first launch for new quinolone

Pliva presents new azithromycin derivatives at ICMASKO 5

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...